The analysis describes how predictive biomarkers are changing the global landscape of neuroregeneration and transitioning from the concept of control of brain injury to an active repair of the brain. This analysis also describes how blood-based biomarkers are replacing imaging-based approaches to assess brain injury. It explores the development of blood tests to measure the burden of Alzheimer’s disease, detect brain injury following acute events such as stroke, and identify early nerve fiber damage that may occur years before the onset of symptoms associated with diseases such as MS (multiple sclerosis), ALS (amyotrophic lateral sclerosis), and dementia. Furthermore, this analysis describes the various types of biomarkers that comprise an integrated approach to the measurement of brain function and health, describes how biomarkers are being used to categorize patients, time interventions to windows of opportunity for repair, and use pharmacodynamic biomarker data as an indication of what drugs will repair the brain, and serve as an indication of how long the brain will take to recover from injuries. This analysis also explores the answers to questions such as:

• Are your teams prepared to shift from the concept of control of brain injury to an active repair of the brain through predictive biomarkers?
• In what ways can predictive biomarkers enable more precise patient stratification, optimize intervention timing, and guide brain repair and recovery?
• What partnerships and new business models will help combine diagnostic tests, therapeutic delivery systems and the delivery of data services to offer outcomes-based solutions?